Literature DB >> 26851501

Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.

Deisy Guiretti1, Ana Sempere2, Jose P Lopez-Atalaya1, Antonio Ferrer-Montiel2, Angel Barco3, Luis M Valor4.   

Abstract

Defective epigenetic regulation has been postulated as a possible cause for the extensive and premature transcriptional dysregulation observed in experimental models of Huntington's disease (HD). In this study, we extended our observations in the N171-82Q mouse strain relating to the limited impact of polyQ pathology on the global histone acetylation to other animal and cellular models of HD, namely the R6/1 and YAC128 strains, striatal-electroporated mice, primary neuronal cultures and stably transfected PC12 cells. In the absence of bulk chromatin changes, we nonetheless documented histone deacetylation events at the transcription start sites (TSS) of genes relevant to neuronal functions (e.g., Rin1, Plk5, Igfbp5, Eomes, and Fos). In some instances, these local deficits were associated with an increased susceptibility to transcriptional dysregulation (e.g., Camk1g and Rasl11b) and the defective trimethylation of histone H3 at lysine 4 (H3K4me3), another covalent modification of histone tails that is related to active transcription and is also altered in HD. Overall, this study provides further insight into the nature and extent of epigenetic dysregulation in HD pathology.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epigenetics; Histone acetylation; Histone methylation; Huntington's disease; Polyglutamine; Transcriptional dysregulation

Mesh:

Substances:

Year:  2016        PMID: 26851501     DOI: 10.1016/j.nbd.2016.02.004

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  6 in total

Review 1.  Contribution of Neuroepigenetics to Huntington's Disease.

Authors:  Laetitia Francelle; Caroline Lotz; Tiago Outeiro; Emmanuel Brouillet; Karine Merienne
Journal:  Front Hum Neurosci       Date:  2017-01-30       Impact factor: 3.169

2.  Understanding histone deacetylation in Huntington's disease.

Authors:  Luis Miguel Valor
Journal:  Oncotarget       Date:  2017-01-24

Review 3.  Roles of the Neuron-Restrictive Silencer Factor in the Pathophysiological Process of the Central Nervous System.

Authors:  Xin-Jin Su; Bei-Duo Shen; Kun Wang; Qing-Xin Song; Xue Yang; De-Sheng Wu; Hong-Xing Shen; Chao Zhu
Journal:  Front Cell Dev Biol       Date:  2022-03-01

4.  Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator.

Authors:  Snehajyoti Chatterjee; Raphaelle Cassel; Anne Schneider-Anthony; Karine Merienne; Brigitte Cosquer; Laura Tzeplaeff; Sarmistha Halder Sinha; Manoj Kumar; Piyush Chaturbedy; Muthusamy Eswaramoorthy; Stéphanie Le Gras; Céline Keime; Olivier Bousiges; Patrick Dutar; Petnoi Petsophonsakul; Claire Rampon; Jean-Christophe Cassel; Luc Buée; David Blum; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  EMBO Mol Med       Date:  2018-11       Impact factor: 12.137

5.  Early alteration of epigenetic-related transcription in Huntington's disease mouse models.

Authors:  Irati Hervás-Corpión; Deisy Guiretti; Manuel Alcaraz-Iborra; Román Olivares; Antonio Campos-Caro; Ángel Barco; Luis M Valor
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

6.  Transcriptional correlates of the pathological phenotype in a Huntington's disease mouse model.

Authors:  Andrea Gallardo-Orihuela; Irati Hervás-Corpión; Carmen Hierro-Bujalance; Daniel Sanchez-Sotano; Gema Jiménez-Gómez; Francisco Mora-López; Antonio Campos-Caro; Monica Garcia-Alloza; Luis M Valor
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.